Greenlane Holdings is a Nasdaq-listed company holding about 81.3 million BERA and BERA-equivalent units. Its token treasury ended the second quarter valued at about 77% below cost. A stayed Nasdaq rule could eventually expose the company to a $5 million listing test with no ordinary cure period.
At June 30, the treasury's $70.2 million cost basis compared with $16.4 million of fair value, according to Greenlane's quarterly filing. The 76.6% gap was a mark-to-market shortfall, not a realized loss from selling the tokens.
CryptoSlate Berachain market data puts the price at roughly $0.142. At that price, the same 81.3 million units would be worth about $11.6 million. That estimate is illustrative, not a company-reported current value. It assumes the holding was unchanged after quarter-end and that all BERA-equivalent positions value one-for-one.
Greenlane's liquidity and losses
Greenlane reported $6.1 million of cash at June 30, down from $32.5 million at the end of 2025. In addition, it held $8.1 million of aUSDC and sUSDe protocol instruments, presented separately from cash, against $6.5 million of current liabilities. The filing flags liquidity, redemption, counterparty, protocol and valuation risks around those instruments.
The company's $24.8 million second-quarter net loss included a $19.1 million noncash change in digital-asset fair value. It also included a separate $1.8 million impairment of its Airgraft investment. Meanwhile, Greenlane's operating loss was $3.3 million, while cash used in operations totaled about $7.1 million for the first half. These figures separate the accounting hit from cash consumed by the business.





